The big move in pharma these days is away from primary-care drugs for chronic maladies such as high blood pressure and diabetes, and toward high-priced specialty medicines for diseases such as cancer. But Roche, which has tended to focus more on specialty medicines, may be moving in the other direction.
In an interview with the Financial [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment